Methodology and Scope

Executive Summary

Executive Summary (continued)

Executive Summary (continued)

Executive Summary (continued)

Executive Summary (continued)

Executive Summary (continued)

Executive Summary (continued)

Introduction

Physician Guidelines to Opioid Therapy—Moderate to Severe Chronic Pain

Physician Guidelines to Opioid Therapy—Neuropathic Pain

Physician Guidelines to Opioid Therapy—Cancer-induced Pain

Physician Guidelines to Opioid Therapy—Acute and Post-operative Pain

Introduction—Chronic Pain Prevalence by Severity

Opioid Pain Market by Region

Top-selling Products in the US Opioid Therapeutics Market

Opioid Therapeutics—Percent Sales by Type of Pain

Opioid Therapeutics—Pain Formulation Prescription Sales

Opioid Therapeutics—TRF and Non-TRF Prescription Sales

Opioid Therapeutics—Estimated Peak Sales by Route of Administration

Opioid Therapeutics Market—Pain Patch Products

Game-changing Strategies

Companies to Watch

Opioid Therapeutics Market—Competitive Landscape

Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market

Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)

Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)

Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)

Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)

Pipeline Analysis—Moderate to Severe Chronic Pain Opioid Therapeutics

Pipeline Analysis—Moderate to Severe Chronic Pain Opioid Therapeutics (continued)

Pipeline Analysis—Moderate to Severe Chronic Pain Opioid Therapeutics (continued)

Marketed Product—Neuropathic Pain Opioid Therapeutics

Pipeline Analysis—Neuropathic Pain Opioid Therapeutics

Pipeline Analysis—Neuropathic Pain Opioid Therapeutics (continued)

Marketed Product Synopsis—Cancer-induced Pain Opioid Therapeutics

Marketed Product Synopsis—Cancer-induced Pain Opioid Therapeutics (continued)

Pipeline Analysis—Cancer-induced Pain Opioid Therapeutics

Marketed Product Synopsis—Post-operative and Acute Pain Opioid Therapeutics

Pipeline Analysis—Post-operative and Acute Pain Opioid Therapeutics

Moderate to Severe Chronic Pain Clinical Trial Design Comparison—Phase 3

Moderate to Severe Chronic Pain Clinical Trial Design Comparison—Phase 3 (continued)

Moderate to Severe Chronic Pain Clinical Trial Design Comparison—Phase 3 (continued)

Cancer-induced Pain Clinical Development Synopsis—Phase 3

Post-operative and Acute Pain Clinical Trial Design Comparison—Phase 3

Estimated US Product Launch Timeline

Pre-launch Products Clinical Program—Remoxy and HYD Tablets

Pipeline Products Clinical Phase 3 Studies—BEMA Buprenorphine, COL-003, Nucynta

Pipeline Products Clinical Phase 3 Studies—Zalviso

Product Dashboard: Remoxy (Durect/Pain Therapeutics)

Product Dashboard: BEMA Buprenorphine (Endo Pharmaceuticals/Biodelivery)

Product Dashboard: HYD Tablet (Purdue Pharma)

Product Dashboard: COL-003/Oxycodone DETERx (Collegium)

Product Dashboard: Nucynta Extended Release (Grünenthal/J&J)

Product Dashboard: MoxDuo Immediate Release (Actavis/QRxPharma)

The Last Word

Legal Disclaimer

The Frost & Sullivan Story

Value Proposition: Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy